Simbrinza, a fixed combination of Brinzolamide 1% and Brimonidine 0.2%, is used primarily to treat open-angle glaucoma, a condition characterized by elevated intraocular pressure (IOP). The question many researchers are asking is: how effective is it in controlling IOP over a 24-hour period?
Results from a randomized trial conducted across multiple centers demonstrated that Brinzolamide/Brimonidine (Simbrinza) fixed combination (BBFC) offered effective 24-hour IOP control. A total of 560 patients with primary open-angle glaucoma or ocular hypertension with insufficient IOP reduction or receiving ≥ 2 IOP-lowering medications participated in this study. At month 3, BBFC significantly lowered the mean diurnal IOP from baseline compared to Brinzolamide and Brimonidine alone.
The study also showed that BBFC given twice daily had a significantly greater IOP-lowering effect than either Brinzolamide or Brimonidine. Furthermore, BBFC also showed a similar safety profile compared to its individual components.
Moreover, the greater IOP-lowering effect of BBFC versus each of its components was observed as early as week 2 and was sustained throughout the 6 months of treatment. These findings suggest that Brinzolamide/Brimonidine (Simbrinza) provides early and sustained IOP control which is crucial for long-term management of glaucoma.
In conclusion, the efficacy of Brinzolamide/Brimonidine (Simbrinza) in controlling IOP over a 24-hour period and its ability in providing sustained IOP control make it a valuable option for individuals dealing with open-angle glaucoma.
Reference:- Aung T, Laganovska G, Hernandez Paredes TJ, Branch JD, Tsorbatzoglou A, Goldberg I. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology. 2014 Dec;121(12):2348-55. doi: 10.1016/j.ophtha.2014.06.022. Epub 2014 Jul 23. Erratum in: Ophthalmology. 2015 Oct;122(10):2149. PMID: 25064721.